Compare PHAR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | PCRX |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2020 | 2010 |
| Metric | PHAR | PCRX |
|---|---|---|
| Price | $13.00 | $22.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $38.33 | $30.25 |
| AVG Volume (30 Days) | 9.6K | ★ 497.0K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $10.04 | $6.78 |
| Revenue Next Year | $2.51 | $8.54 |
| P/E Ratio | $3,041.22 | ★ $333.79 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $8.69 | $18.80 |
| 52 Week High | $21.34 | $27.64 |
| Indicator | PHAR | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.63 | 39.46 |
| Support Level | $11.02 | $22.13 |
| Resistance Level | $17.79 | $24.20 |
| Average True Range (ATR) | 0.38 | 1.27 |
| MACD | -0.52 | -0.30 |
| Stochastic Oscillator | 15.00 | 4.28 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.